PTC Therapeutics Inc. (NASDAQ:PTCT)’s share price traded down 0.8% on Friday . The stock traded as low as $7.22 and last traded at $7.45, with a volume of 432,136 shares changing hands. The stock had previously closed at $7.51.

Several equities analysts have weighed in on the company. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $39.00 price objective on shares of PTC Therapeutics in a report on Sunday, April 17th. Zacks Investment Research lowered PTC Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Wedbush reissued a “neutral” rating and set a $11.00 price objective on shares of PTC Therapeutics in a report on Wednesday, March 23rd. Jefferies Group reissued a “hold” rating and set a $8.00 price objective on shares of PTC Therapeutics in a report on Friday, May 6th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $9.00 price objective on shares of PTC Therapeutics in a report on Monday, April 18th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $36.05.

The stock has a 50-day moving average price of $7.37 and a 200-day moving average price of $13.27. The company’s market capitalization is $255.41 million.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.04. During the same period last year, the firm posted ($1.15) earnings per share. The company earned $18.90 million during the quarter, compared to analysts’ expectations of $13.74 million. PTC Therapeutics’s revenue was up 152.0% on a year-over-year basis. Equities analysts expect that PTC Therapeutics Inc. will post ($4.93) EPS for the current year.

A number of large investors have made changes to their positions in the company. California State Teachers Retirement System increased its stake in shares of PTC Therapeutics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 62,719 shares of the biopharmaceutical company’s stock valued at $2,032,000 after buying an additional 1,100 shares during the last quarter. Rhumbline Advisers increased its stake in shares of PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 2,485 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of PTC Therapeutics by 10.6% in the fourth quarter. ProShare Advisors LLC now owns 32,490 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 3,122 shares during the last quarter. Gratus Capital LLC increased its stake in shares of PTC Therapeutics by 9.7% in the fourth quarter. Gratus Capital LLC now owns 53,350 shares of the biopharmaceutical company’s stock valued at $1,729,000 after buying an additional 4,700 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock valued at $1,439,000 after buying an additional 14,926 shares during the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.